Currently, ligand-mediated RNAi conjugates lead the market. However, future growth is anticipated in ligand-attached anti-sense therapies. In terms of targeting ligand types, peptides currently hold a ...

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...

Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials ...

The ADC market offers significant growth opportunities driven by the rising cancer incidence and demand for targeted ...

Key market opportunities in next-generation drug conjugates are driven by their precision in targeting rare diseases and cancers, owing to their enhanced clinical profiles and varied targeting agents ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

Trastuzumab deruxtecan in frontline maintenance Dr Moore discussed the challenge of prioritizing biomarkers when multiple are present: “I would always prioritize a ...

Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective" report has ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...